Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA accepts for review Protalix Biotherapeutics' resubmitted NDA for taliglucerase alfa

Aug. 18, 2011

Nippon Chemiphar presents new GPR119 receptor agonists

Aug. 18, 2011

FDA approved new strengths of Lupron Depot-PED allowing administration every 3 months

Aug. 17, 2011

Omthera Pharmaceuticals begins phase III ESPRIT trial

Aug. 17, 2011

NIH to support studies of Lpath immunotherapy in diabetic neuropathy

Aug. 17, 2011

MannKind confirms with FDA protocols for two Afrezza trials in diabetes

Aug. 16, 2011

Pronova BioPharma submits application for phase I trial of omega-3 fatty acid derivative

Aug. 16, 2011

Teijin and Astellas enter agreement for febuxostat

Aug. 16, 2011

FDA sets new PDUFA action date for Bydureon

Aug. 12, 2011

New molecules for diabetic foot ulcers prepared

Aug. 12, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...